Supplemental sulfone (dapsone) therapy. Use in treatment of chloroquine-resistant falciparum malaria.
D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000139:chemically induced; D055598:Chemical Phenomena; D002627:Chemistry, Physical / Q000627:therapeutic use*; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D008887:Military Medicine; D010963:Plasmodium falciparum / Q000187:drug effects*; D011605:Psychoses, Substance-Induced; D011803:Quinine / Q000627:therapeutic use*; D014481:United States; D014744:Vietnam; D044465:White People
D003622:Dapsone; D011803:Quinine